Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

NCT03739138 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: MK-4621
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC